http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Sep 2025 01:06:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Roche+To+Buy+US-listed+89bio+For+%2414.50shr/25347490.html <p>Roche To Buy 89bio For $14.50/shr</p><ul><li>89bio closed at $8.08 on Wednesday</li><li>Deal aimed at acquiring 89bio's phase-3 metabolic dysfunction-associated steatohepatitis candidates </li></ul> http://www.streetinsider.com/Mergers+and+Acquisitions/Roche+To+Buy+US-listed+89bio+For+%2414.50shr/25347490.html Thu, 18 Sep 2025 01:06:24 -0400 ETNB RHHVF http://www.streetinsider.com/Mergers+and+Acquisitions/Roche+To+Buy+US-listed+89bio+For+%2414.50shr/25347490.html <p>Roche To Buy 89bio For $14.50/shr</p><ul><li>89bio closed at $8.08 on Wednesday</li><li>Deal aimed at acquiring 89bio's phase-3 metabolic dysfunction-associated steatohepatitis candidates </li></ul> http://www.streetinsider.com/Mergers+and+Acquisitions/Roche+To+Buy+US-listed+89bio+For+%2414.50shr/25347490.html Thu, 18 Sep 2025 01:06:24 -0400 ETNB RHHVF http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html <p>Investing.com -- AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).</p> <p>The company noted that the safety and tolerability seen in the RESOLUTE trial were in line with the medicine’s existing profile. It added that a full analysis of the trial results will be conducted and later shared with the scientific community.</p> <p>Fasenra is already approved as an add-on therapy for severe eosinophilic asthma in more than 80 markets, including the U.S., EU, Japan and China.</p> <p>It is also cleared in the U.S. and Japan http://www.streetinsider.com/Investing/AstraZeneca+says+Fasenra+misses+main+goal+in+COPD+trial/25342955.html Wed, 17 Sep 2025 06:49:13 -0400 AZN AZNA AZNCF AZNN GLAXF GSK GSKN MRK RHHBY RHHVF RO ROCHE ROG ROGN SANF SASY SNY SNYN http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html <p>Investing.com -- <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Sarepta </span></span> Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.</p> <p>The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able to walk, the agency announced Friday. The therapy, which is marketed outside the U.S. by Roche Holding AG (SIX:ROG), was seeking approval for treating the rare genetic disease that causes progressive muscle weakness.</p> <p>This setback follows closely on the heels of the U.S. Food and Drug Administration’s recent request for a pause http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html Fri, 25 Jul 2025 11:14:30 -0400 RHHBY RHHVF RO ROG SRPT http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html <p>Investing.com -- <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Sarepta </span></span> Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.</p> <p>The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able to walk, the agency announced Friday. The therapy, which is marketed outside the U.S. by Roche Holding AG (SIX:ROG), was seeking approval for treating the rare genetic disease that causes progressive muscle weakness.</p> <p>This setback follows closely on the heels of the U.S. Food and Drug Administration’s recent request for a pause http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html Fri, 25 Jul 2025 11:14:30 -0400 RHHBY RHHVF RO ROG SRPT http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html <p>Investing.com -- <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Sarepta </span></span> Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.</p> <p>The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able to walk, the agency announced Friday. The therapy, which is marketed outside the U.S. by Roche Holding AG (SIX:ROG), was seeking approval for treating the rare genetic disease that causes progressive muscle weakness.</p> <p>This setback follows closely on the heels of the U.S. Food and Drug Administration’s recent request for a pause http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html Fri, 25 Jul 2025 11:14:30 -0400 RHHBY RHHVF RO ROG SRPT http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html <p>Investing.com -- <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Sarepta </span></span> Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.</p> <p>The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able to walk, the agency announced Friday. The therapy, which is marketed outside the U.S. by Roche Holding AG (SIX:ROG), was seeking approval for treating the rare genetic disease that causes progressive muscle weakness.</p> <p>This setback follows closely on the heels of the U.S. Food and Drug Administration’s recent request for a pause http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html Fri, 25 Jul 2025 11:14:30 -0400 RHHBY RHHVF RO ROG SRPT http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html <p>Investing.com -- <span itemscope itemtype="http://schema.org/Corporation"><span itemprop="name"> Sarepta </span></span> Therapeutics Inc. (NASDAQ:SRPT) stock declined 13% Friday after European regulators recommended against approving Elevidys, the company’s gene therapy for Duchenne muscular dystrophy.</p> <p>The European Medicines Agency’s drug advisory committee (CHMP) rejected Elevidys for children aged 3 to 7 years who are able to walk, the agency announced Friday. The therapy, which is marketed outside the U.S. by Roche Holding AG (SIX:ROG), was seeking approval for treating the rare genetic disease that causes progressive muscle weakness.</p> <p>This setback follows closely on the heels of the U.S. Food and Drug Administration’s recent request for a pause http://www.streetinsider.com/Investing/Sarepta+stock+falls+after+Elevidys+fails+to+get+backing+by+EU+regulators/25099012.html Fri, 25 Jul 2025 11:14:30 -0400 RHHBY RHHVF RO ROG SRPT